← FDA DRUG APPROVALS

FDA ANDA · ANDA064192

CEFUROXIME SODIUM

Sponsor: TEVA PHARMS

APPLICATION
ANDA064192
TYPE
ANDA
ORIGINAL APPROVAL
1998-04-16
LATEST ACTION
2002-12-12
ROUTE
INTRAMUSCULAR, INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFUROXIME SODIUMDiscontinued
CEFUROXIME SODIUM EQ 750MG BASE/VIAL · INJECTABLE · INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUMDiscontinued
CEFUROXIME SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE · INTRAMUSCULAR, INTRAVENOUS

Approval history

2002-12-12Manufacturing (CMC) · Supplement 1AP
1998-04-16Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →